Kala Bio vs Oculis
KALA and OCS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KALA and OCS compare
Kala Bio scores higher on the StockData Score (6 against 1 for Oculis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KALA | OCS |
|---|---|---|
| Size and price | ||
| Market cap | $2.7M | – |
| Share price | $0.139 | $7.64 |
| Change, 1 year | −99.6% | −59.6% |
| Change, 5 years | −100.0% | −21.7% |
| Beta (5Y) | 0.34 | 0.43 |
| Employees | 6 | 60 |
| StockData Score | ||
| Total score | 6 (better) | 1 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.3× | – |
| Profitability | ||
| Return on equity | −345% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −98.0× |
| Current ratio | 6.88 | 8.35 (better) |
| Altman Z-score | −96.83 | – |
| Piotroski F-score | 2 | – |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 3.2% | – |
| Held by insiders | – | 11.6% |
| Insider net buying, 12 months | $0 | – |
Go deeper
- KALA stock overview
- KALA income statement
- KALA valuation and score
- OCS stock overview
- OCS income statement
- OCS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.